This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Learn more here.
Christopher S.  Boerner net worth and biography

Christopher Boerner Biography and Net Worth

Christopher Boerner is chief commercialization officer of Bristol Myers Squibb, where he leads commercial strategy and execution across all geographies. He also currently serves as the executive sponsor of the Bristol Myers Squibb Network of Women (B-NOW) People and Business Resource Group. In his previous role, Chris was head of international markets at Bristol Myers Squibb, accountable for commercial activities in all ex-U.S. markets. He joined the company in February 2015. 

“I look forward to continuing to help BMS deliver on our mission of bringing transformational medicines to patients,” Chris said. “By focusing on innovation and execution, we can strengthen our ability to bring innovative medicines to patients faster.”

Prior to joining Bristol Myers Squibb, Chris served as the executive vice president of commercial for Seattle Genetics, Inc., where he led all commercial activities for the company, as well as senior vice president of commercial and vice president of marketing.

Before joining Seattle Genetics, Chris worked for Dendreon Corporation, where he led the marketing team. From 2002 to 2010, he worked for Genentech, a member of the Roche Group, where he served in a variety of commercial roles, including director of marketing on Avastin®. Prior to Genentech, he worked for McKinsey & Company, serving global pharmaceutical and biotechnology clients.

Chris received his PhD and MA in business administration from the Haas School of Business at the University of California, Berkeley, and holds an AB in economics and history from Washington University in St. Louis.

What is Christopher S. Boerner's net worth?

The estimated net worth of Christopher S. Boerner is at least $4.21 million as of December 5th, 2023. Dr. Boerner owns 82,672 shares of Bristol-Myers Squibb stock worth more than $4,207,178 as of March 3rd. This net worth approximation does not reflect any other assets that Dr. Boerner may own. Additionally, Dr. Boerner receives a salary of $2,620,000.00 as EVP at Bristol-Myers Squibb. Learn More about Christopher S. Boerner's net worth.

How old is Christopher S. Boerner?

Dr. Boerner is currently 53 years old. There are 7 older executives and no younger executives at Bristol-Myers Squibb. The oldest executive at Bristol-Myers Squibb is Dr. Joseph J. Eiden Jr., Head of Medical Affairs, who is 75 years old. Learn More on Christopher S. Boerner's age.

What is Christopher S. Boerner's salary?

As the EVP of Bristol-Myers Squibb, Dr. Boerner earns $2,620,000.00 per year. There are 3 executives that earn more than Dr. Boerner. The highest earning executive at Bristol-Myers Squibb is Dr. Giovanni Caforio M.D., Executive Chairman of the Board, who commands a salary of $5,760,000.00 per year. Learn More on Christopher S. Boerner's salary.

How do I contact Christopher S. Boerner?

The corporate mailing address for Dr. Boerner and other Bristol-Myers Squibb executives is 430 E. 29TH STREET 14 FLOOR, NEW YORK NY, 10016. Bristol-Myers Squibb can also be reached via phone at (212) 546-4000 and via email at [email protected]. Learn More on Christopher S. Boerner's contact information.

Has Christopher S. Boerner been buying or selling shares of Bristol-Myers Squibb?

Christopher S. Boerner has not been actively trading shares of Bristol-Myers Squibb during the last ninety days. Most recently, on Tuesday, December 5th, Christopher S. Boerner bought 2,000 shares of Bristol-Myers Squibb stock. The stock was acquired at an average cost of $49.78 per share, with a total value of $99,560.00. Following the completion of the transaction, the chief executive officer now directly owns 82,672 shares of the company's stock, valued at $4,115,412.16. Learn More on Christopher S. Boerner's trading history.

Who are Bristol-Myers Squibb's active insiders?

Bristol-Myers Squibb's insider roster includes Mark Alles (CEO), Christopher Boerner (EVP), Giovanni Caforio (CEO), Adam Dubow (SVP), Joseph Eid (SVP), John Elicker (EVP), David Elkins (CFO), Sandra Leung (EVP), Dinesh Paliwal (Director), Robert Plenge (EVP), Ann Powell (EVP), Theodore Samuels, II (Director), Karen Santiago (SVP), Louis Schmukler (EVP), Rupert Vessey (EVP), and Paul von Autenried (EVP). Learn More on Bristol-Myers Squibb's active insiders.

Are insiders buying or selling shares of Bristol-Myers Squibb?

During the last year, Bristol-Myers Squibb insiders bought shares 3 times. They purchased a total of 13,571 shares worth more than $672,994.06. During the last year, insiders at the biopharmaceutical company sold shares 3 times. They sold a total of 69,103 shares worth more than $4,525,215.08. The most recent insider tranaction occured on December, 5th when CEO Christopher S Boerner bought 2,000 shares worth more than $99,560.00. Insiders at Bristol-Myers Squibb own 0.1% of the company. Learn More about insider trades at Bristol-Myers Squibb.

Information on this page was last updated on 12/5/2023.

Christopher S. Boerner Insider Trading History at Bristol-Myers Squibb

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/5/2023Buy2,000$49.78$99,560.0082,672View SEC Filing Icon  
11/28/2023Buy3,071$48.86$150,049.0679,384View SEC Filing Icon  
3/14/2022Sell29,532$69.20$2,043,614.40View SEC Filing Icon  
See Full Table

Christopher S. Boerner Buying and Selling Activity at Bristol-Myers Squibb

This chart shows Christopher S Boerner's buying and selling at Bristol-Myers Squibb by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Bristol-Myers Squibb Company Overview

Bristol-Myers Squibb logo
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New York.
Read More

Today's Range

Now: $50.89
Low: $50.44
High: $51.08

50 Day Range

MA: $50.31
Low: $48.00
High: $52.79

2 Week Range

Now: $50.89
Low: $47.58
High: $71.07

Volume

10,892,290 shs

Average Volume

13,595,074 shs

Market Capitalization

$102.91 billion

P/E Ratio

13.18

Dividend Yield

4.72%

Beta

0.38
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Full details and steps to take here.